vs

Side-by-side financial comparison of AEHR TEST SYSTEMS (AEHR) and Assertio Holdings, Inc. (ASRT). Click either name above to swap in a different company.

Assertio Holdings, Inc. is the larger business by last-quarter revenue ($13.5M vs $9.9M, roughly 1.4× AEHR TEST SYSTEMS). On growth, AEHR TEST SYSTEMS posted the faster year-over-year revenue change (-26.5% vs -57.9%). Over the past eight quarters, AEHR TEST SYSTEMS's revenue compounded faster (14.3% CAGR vs -35.4%).

Aehr Test Systems designs, manufactures and sells advanced test and burn-in systems for the global semiconductor industry. Its products help semiconductor manufacturers, packaging firms and chip designers validate reliability of logic, memory and power semiconductor devices, serving markets across North America, Asia and Europe.

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

AEHR vs ASRT — Head-to-Head

Bigger by revenue
ASRT
ASRT
1.4× larger
ASRT
$13.5M
$9.9M
AEHR
Growing faster (revenue YoY)
AEHR
AEHR
+31.4% gap
AEHR
-26.5%
-57.9%
ASRT
Faster 2-yr revenue CAGR
AEHR
AEHR
Annualised
AEHR
14.3%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AEHR
AEHR
ASRT
ASRT
Revenue
$9.9M
$13.5M
Net Profit
$-3.2M
Gross Margin
25.7%
Operating Margin
-47.0%
-86.7%
Net Margin
-32.7%
Revenue YoY
-26.5%
-57.9%
Net Profit YoY
-214.2%
EPS (diluted)
$-0.11
$-4.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AEHR
AEHR
ASRT
ASRT
Q4 25
$9.9M
$13.5M
Q3 25
$11.0M
$49.5M
Q2 25
$14.1M
$29.2M
Q1 25
$18.3M
$26.5M
Q4 24
$13.5M
$32.2M
Q3 24
$13.1M
$29.2M
Q2 24
$16.6M
$31.1M
Q1 24
$7.6M
$32.4M
Net Profit
AEHR
AEHR
ASRT
ASRT
Q4 25
$-3.2M
Q3 25
$-2.1M
$11.4M
Q2 25
$-2.9M
$-16.4M
Q1 25
$-643.0K
$-13.5M
Q4 24
$-1.0M
Q3 24
$660.0K
$-2.9M
Q2 24
$23.9M
$-3.7M
Q1 24
$-1.5M
$-4.5M
Gross Margin
AEHR
AEHR
ASRT
ASRT
Q4 25
25.7%
Q3 25
33.9%
Q2 25
30.3%
Q1 25
39.2%
Q4 24
40.1%
Q3 24
54.0%
Q2 24
50.9%
Q1 24
41.7%
Operating Margin
AEHR
AEHR
ASRT
ASRT
Q4 25
-47.0%
-86.7%
Q3 25
-37.1%
23.2%
Q2 25
-22.7%
-27.5%
Q1 25
-6.1%
-50.0%
Q4 24
-11.2%
-41.9%
Q3 24
1.2%
-10.4%
Q2 24
15.3%
-11.6%
Q1 24
-27.1%
-13.4%
Net Margin
AEHR
AEHR
ASRT
ASRT
Q4 25
-32.7%
Q3 25
-19.0%
23.1%
Q2 25
-20.6%
-56.0%
Q1 25
-3.5%
-51.1%
Q4 24
-7.6%
Q3 24
5.0%
-10.0%
Q2 24
143.8%
-11.8%
Q1 24
-19.4%
-13.9%
EPS (diluted)
AEHR
AEHR
ASRT
ASRT
Q4 25
$-0.11
$-4.54
Q3 25
$-0.07
$0.11
Q2 25
$-0.10
$-0.17
Q1 25
$-0.02
$-0.14
Q4 24
$-0.03
$-3.28
Q3 24
$0.02
$-0.03
Q2 24
$0.81
$-0.04
Q1 24
$-0.05
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AEHR
AEHR
ASRT
ASRT
Cash + ST InvestmentsLiquidity on hand
$30.8M
$63.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$130.8M
$94.0M
Total Assets
$148.7M
$267.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AEHR
AEHR
ASRT
ASRT
Q4 25
$30.8M
$63.4M
Q3 25
$22.7M
$93.4M
Q2 25
$24.5M
$98.2M
Q1 25
$29.4M
$87.3M
Q4 24
$32.2M
$100.1M
Q3 24
$37.8M
$88.6M
Q2 24
$49.2M
$88.4M
Q1 24
$47.6M
$80.7M
Total Debt
AEHR
AEHR
ASRT
ASRT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
AEHR
AEHR
ASRT
ASRT
Q4 25
$130.8M
$94.0M
Q3 25
$122.4M
$105.8M
Q2 25
$122.9M
$93.3M
Q1 25
$124.2M
$108.5M
Q4 24
$123.2M
$121.1M
Q3 24
$122.5M
$130.5M
Q2 24
$111.6M
$132.2M
Q1 24
$86.5M
$134.5M
Total Assets
AEHR
AEHR
ASRT
ASRT
Q4 25
$148.7M
$267.0M
Q3 25
$144.1M
$319.8M
Q2 25
$148.5M
$273.8M
Q1 25
$145.6M
$286.4M
Q4 24
$142.3M
$284.7M
Q3 24
$145.9M
$276.0M
Q2 24
$127.9M
$279.4M
Q1 24
$101.6M
$282.0M
Debt / Equity
AEHR
AEHR
ASRT
ASRT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AEHR
AEHR
ASRT
ASRT
Operating Cash FlowLast quarter
$-1.2M
$-30.0M
Free Cash FlowOCF − Capex
$-1.6M
FCF MarginFCF / Revenue
-16.6%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-11.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AEHR
AEHR
ASRT
ASRT
Q4 25
$-1.2M
$-30.0M
Q3 25
$-282.0K
$-4.8M
Q2 25
$-2.3M
$19.1M
Q1 25
$-1.6M
$-12.5M
Q4 24
$-5.9M
$11.5M
Q3 24
$2.4M
$-35.0K
Q2 24
$1.2M
$7.4M
Q1 24
$-2.8M
$7.5M
Free Cash Flow
AEHR
AEHR
ASRT
ASRT
Q4 25
$-1.6M
Q3 25
$-1.7M
Q2 25
$-5.1M
Q1 25
$-3.3M
Q4 24
$-6.2M
Q3 24
$2.2M
Q2 24
$1.2M
Q1 24
$-3.1M
FCF Margin
AEHR
AEHR
ASRT
ASRT
Q4 25
-16.6%
Q3 25
-15.3%
Q2 25
-36.3%
Q1 25
-17.8%
Q4 24
-46.0%
Q3 24
16.6%
Q2 24
7.1%
Q1 24
-40.8%
Capex Intensity
AEHR
AEHR
ASRT
ASRT
Q4 25
4.7%
Q3 25
12.7%
Q2 25
20.0%
Q1 25
9.0%
Q4 24
2.4%
Q3 24
1.5%
0.0%
Q2 24
0.3%
Q1 24
3.5%
Cash Conversion
AEHR
AEHR
ASRT
ASRT
Q4 25
Q3 25
-0.42×
Q2 25
Q1 25
Q4 24
Q3 24
3.61×
Q2 24
0.05×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AEHR
AEHR

Systems$5.0M50%
Contactors$3.4M35%
Services$1.5M15%

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

Related Comparisons